FDA Makes Post-Market Safety Evaluation Comprehensive For All NMEs, BLAs
All new molecular entities and BLAs approved since Sept. 27, 2007, will be subject to the comprehensive post-market safety evaluation process that FDA pilot-tested during the past two years
You may also be interested in...
Agency's decision means that analysis of Doribax, Isentress and Bystolic will be forthcoming.
FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain
FDA outlines organizational steps and safety monitoring initiatives in response to IoM report on improving drug safety.